\begin{longtable}{p{0.16\textwidth}p{0.12\textwidth}p{0.12\textwidth}p{0.12\textwidth}p{0.12\textwidth}p{0.12\textwidth}p{0.12\textwidth}}
   & 2018 Jan-Jun & 2018 Jul-Dec & 2019 Jan-Jun & 2019 Jul-Dec & 2020 Jan-Jun & 2020 Jul-Dec \\ 
  \hline 
\endfirsthead 
\multicolumn{7}{p{\textwidth}}{{ \bfseries \tablename \thetable{} -- continued from previous page}} \ 
\hline Feature & 2018 Jan-Jun & 2018 Jul-Dec & 2019 Jan-Jun & 2019 Jul-Dec & 2020 Jan-Jun & 2020 Jul-Dec \\ \hline 
\endhead 
\hline \multicolumn{7}{p{\textwidth}}{{Continued on next page}} \\ \hline 
\endfoot 
\hline 
\endlastfoot 
 \hline
 & (N=9642) & (N=10778) & (N=13871) & (N=13596) & (N=13412) & (N=16765) \\ 
  Age &  &  &  &  &  &  \\ 
    Mean (SD) & 58 (12) & 58 (12) & 58 (13) & 58 (13) & 58 (13) & 58 (13) \\ 
  Age Group &  &  &  &  &  &  \\ 
    0-17 & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    18-44 & 1576 (16\%) & 1616 (15\%) & 2134 (15\%) & 2163 (16\%) & 2126 (16\%) & 2625 (16\%) \\ 
    45-64 & 5260 (55\%) & 5886 (55\%) & 7442 (54\%) & 7180 (53\%) & 7043 (53\%) & 8682 (52\%) \\ 
    65+ & 2806 (29\%) & 3276 (30\%) & 4295 (31\%) & 4253 (31\%) & 4243 (32\%) & 5458 (33\%) \\ 
  Sex &  &  &  &  &  &  \\ 
    Female & 5656 (59\%) & 6313 (59\%) & 7909 (57\%) & 7838 (58\%) & 7651 (57\%) & 9763 (58\%) \\ 
    Male & 3959 (41\%) & 4439 (41\%) & 5934 (43\%) & 5719 (42\%) & 5737 (43\%) & 6981 (42\%) \\ 
    Unknown & 27 (0\%) & 26 (0\%) & 28 (0\%) & 39 (0\%) & 24 (0\%) & 21 (0\%) \\ 
  Race &  &  &  &  &  &  \\ 
    White & 7142 (74\%) & 7988 (74\%) & 10041 (72\%) & 9698 (71\%) & 9500 (71\%) & 11742 (70\%) \\ 
    Black & 1671 (17\%) & 1699 (16\%) & 2210 (16\%) & 2341 (17\%) & 2328 (17\%) & 2736 (16\%) \\ 
    Asian & 135 (1\%) & 233 (2\%) & 364 (3\%) & 316 (2\%) & 374 (3\%) & 461 (3\%) \\ 
    AI or AN & 63 (1\%) & 73 (1\%) & 101 (1\%) & 84 (1\%) & 87 (1\%) & 130 (1\%) \\ 
    NH or PI & 30 (0\%) & 34 (0\%) & 50 (0\%) & 49 (0\%) & 53 (0\%) & 70 (0\%) \\ 
    Other Race & 288 (3\%) & 388 (4\%) & 592 (4\%) & 665 (5\%) & 608 (5\%) & 1028 (6\%) \\ 
    Declined to answer & 57 (1\%) & 68 (1\%) & 91 (1\%) & 94 (1\%) & 115 (1\%) & 171 (1\%) \\ 
    Unknown & 256 (3\%) & 295 (3\%) & 422 (3\%) & 349 (3\%) & 347 (3\%) & 427 (3\%) \\ 
  Ethnicity &  &  &  &  &  &  \\ 
    Hispanic or Latino & 576 (6\%) & 741 (7\%) & 1070 (8\%) & 1209 (9\%) & 1200 (9\%) & 1911 (11\%) \\ 
    Not Hispanic or Latino & 8327 (86\%) & 9260 (86\%) & 11770 (85\%) & 11416 (84\%) & 11294 (84\%) & 13796 (82\%) \\ 
    Declined to answer & 84 (1\%) & 105 (1\%) & 161 (1\%) & 159 (1\%) & 152 (1\%) & 203 (1\%) \\ 
    Unknown & 655 (7\%) & 672 (6\%) & 870 (6\%) & 812 (6\%) & 766 (6\%) & 855 (5\%) \\ 
  T2D & 8106 (84\%) & 9063 (84\%) & 11605 (84\%) & 11298 (83\%) & 11074 (83\%) & 13395 (80\%) \\ 
  Obesity or Overweight & 7318 (76\%) & 8134 (75\%) & 10424 (75\%) & 10947 (81\%) & 10558 (79\%) & 12379 (74\%) \\ 
  FDA-labeled Use &  &  &  &  &  &  \\ 
    T2D & 5977 (62\%) & 6783 (63\%) & 8589 (62\%) & 8002 (59\%) & 9142 (68\%) & 12838 (77\%) \\ 
    Obesity & 145 (2\%) & 165 (2\%) & 202 (1\%) & 233 (2\%) & 467 (3\%) & 839 (5\%) \\ 
    Unknown & 3520 (37\%) & 3830 (36\%) & 5080 (37\%) & 5361 (39\%) & 3803 (28\%) & 3088 (18\%) \\ 
  Generic &  &  &  &  &  &  \\ 
    Semaglutide & 287 (3\%) & 1337 (12\%) & 2628 (19\%) & 3946 (29\%) & 4686 (35\%) & 6374 (38\%) \\ 
    Dulaglutide & 3508 (36\%) & 4040 (37\%) & 5309 (38\%) & 4982 (37\%) & 4797 (36\%) & 5903 (35\%) \\ 
    Liraglutide & 4157 (43\%) & 3786 (35\%) & 4561 (33\%) & 3566 (26\%) & 3047 (23\%) & 3603 (21\%) \\ 
    Tirzepatide & 1 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    Exenatide & 1448 (15\%) & 1382 (13\%) & 1149 (8\%) & 921 (7\%) & 691 (5\%) & 685 (4\%) \\ 
    Lixisenatide & 241 (2\%) & 233 (2\%) & 224 (2\%) & 181 (1\%) & 191 (1\%) & 200 (1\%) \\ 
  Brand &  &  &  &  &  &  \\ 
    Ozempic & 44 (0\%) & 201 (2\%) & 448 (3\%) & 774 (6\%) & 1837 (14\%) & 3491 (21\%) \\ 
    Rybelsus & 0 (0\%) & 0 (0\%) & 0 (0\%) & 110 (1\%) & 443 (3\%) & 1019 (6\%) \\ 
    Wegovy & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    Trulicity & 3508 (36\%) & 4040 (37\%) & 5309 (38\%) & 4982 (37\%) & 4797 (36\%) & 5903 (35\%) \\ 
    Victoza & 712 (7\%) & 768 (7\%) & 1103 (8\%) & 568 (4\%) & 790 (6\%) & 1394 (8\%) \\ 
    Saxenda & 145 (2\%) & 165 (2\%) & 202 (1\%) & 233 (2\%) & 467 (3\%) & 839 (5\%) \\ 
    Mounjaro & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    Bydureon & 326 (3\%) & 406 (4\%) & 419 (3\%) & 295 (2\%) & 312 (2\%) & 512 (3\%) \\ 
    Byetta & 32 (0\%) & 75 (1\%) & 62 (0\%) & 19 (0\%) & 17 (0\%) & 36 (0\%) \\ 
    Soliqua & 105 (1\%) & 121 (1\%) & 118 (1\%) & 112 (1\%) & 127 (1\%) & 185 (1\%) \\ 
    Unknown & 4770 (49\%) & 5002 (46\%) & 6210 (45\%) & 6503 (48\%) & 4622 (34\%) & 3386 (20\%) \\ 
  Atrial Fibrilation & 736 (8\%) & 853 (8\%) & 1115 (8\%) & 1144 (8\%) & 1101 (8\%) & 1386 (8\%) \\ 
  Asthma & 1605 (17\%) & 1867 (17\%) & 2383 (17\%) & 2408 (18\%) & 2319 (17\%) & 2874 (17\%) \\ 
  CKD & 1434 (15\%) & 1676 (16\%) & 2182 (16\%) & 2402 (18\%) & 2443 (18\%) & 2928 (17\%) \\ 
  COPD & 964 (10\%) & 1068 (10\%) & 1243 (9\%) & 1352 (10\%) & 1357 (10\%) & 1543 (9\%) \\ 
  Glaucoma & 259 (3\%) & 286 (3\%) & 385 (3\%) & 408 (3\%) & 373 (3\%) & 450 (3\%) \\ 
  Heart Failure & 944 (10\%) & 1043 (10\%) & 1349 (10\%) & 1487 (11\%) & 1502 (11\%) & 1797 (11\%) \\ 
  Hyperlipidemia & 7310 (76\%) & 8215 (76\%) & 10470 (75\%) & 10208 (75\%) & 9913 (74\%) & 11628 (69\%) \\ 
  Hypertension & 7499 (78\%) & 8310 (77\%) & 10627 (77\%) & 10443 (77\%) & 10045 (75\%) & 11774 (70\%) \\ 
  Ischemic Heart Disease & 1084 (11\%) & 1189 (11\%) & 1528 (11\%) & 1613 (12\%) & 1559 (12\%) & 1759 (10\%) \\ 
  Acute MI & 468 (5\%) & 498 (5\%) & 640 (5\%) & 693 (5\%) & 665 (5\%) & 761 (5\%) \\ 
  Ischemic Stroke & 28 (0\%) & 42 (0\%) & 63 (0\%) & 65 (0\%) & 50 (0\%) & 59 (0\%) \\ 
  Major Depressive Disorder & 1874 (19\%) & 2177 (20\%) & 2917 (21\%) & 2846 (21\%) & 2826 (21\%) & 3211 (19\%) \\ 
  Osteoporosis & 301 (3\%) & 347 (3\%) & 471 (3\%) & 470 (3\%) & 429 (3\%) & 582 (3\%) \\ 
  Bariatric Surgery & 180 (2\%) & 219 (2\%) & 286 (2\%) & 274 (2\%) & 298 (2\%) & 336 (2\%) \\ 
  Metformin & 6134 (64\%) & 6686 (62\%) & 8655 (62\%) & 8579 (63\%) & 8428 (63\%) & 9949 (59\%) \\ 
  SGLT2i & 2156 (22\%) & 2294 (21\%) & 2761 (20\%) & 2917 (21\%) & 2843 (21\%) & 3382 (20\%) \\ 
  DPP4 & 2469 (26\%) & 2521 (23\%) & 3026 (22\%) & 3041 (22\%) & 2864 (21\%) & 3079 (18\%) \\ 
  Sulfonylurea & 3268 (34\%) & 3578 (33\%) & 4387 (32\%) & 4503 (33\%) & 4352 (32\%) & 4999 (30\%) \\ 
  Insulin & 1289 (13\%) & 1320 (12\%) & 1665 (12\%) & 1627 (12\%) & 1607 (12\%) & 1938 (12\%) \\ 
  Orlistat & 12 (0\%) & 12 (0\%) & 19 (0\%) & 20 (0\%) & 23 (0\%) & 24 (0\%) \\ 
  Phentermine Topiramate & 90 (1\%) & 115 (1\%) & 116 (1\%) & 85 (1\%) & 80 (1\%) & 73 (0\%) \\ 
  BMI &  &  &  &  &  &  \\ 
    Mean (SD) & 38 (8.2) & 37 (8.2) & 37 (8.4) & 37 (8.4) & 37 (8.4) & 37 (8.6) \\ 
    Missing & 4812 (49.9\%) & 5475 (50.8\%) & 7540 (54.4\%) & 6164 (45.3\%) & 6154 (45.9\%) & 8669 (51.7\%) \\ 
  Weight (in lbs) &  &  &  &  &  &  \\ 
    Mean (SD) & 240 (57) & 230 (58) & 240 (58) & 230 (58) & 230 (59) & 240 (60) \\ 
    Missing & 3270 (33.9\%) & 3997 (37.1\%) & 5781 (41.7\%) & 4580 (33.7\%) & 4943 (36.9\%) & 7907 (47.2\%) \\ 
  HbA1c &  &  &  &  &  &  \\ 
    Mean (SD) & 8.4 (1.9) & 8.4 (1.9) & 8.4 (1.9) & 8.4 (1.9) & 8.4 (2.0) & 8.3 (2.0) \\ 
    Missing & 2232 (23.1\%) & 2500 (23.2\%) & 3057 (22.0\%) & 3068 (22.6\%) & 2974 (22.2\%) & 3746 (22.3\%) \\ 
  \hline
\caption{Characteristics of patients initiating a GLP-1 RA, by period (part 1).\Abbreviations: 
ADM=anti-diabetic medication,
AI  = American Indian, 
AN = Alaska Native, 
AOM=anti-obesity medication, 
Black = Black or African American, 
BMI = body mass index,
CKD=chronic kidney disease, 
COPD=chronic obstructive pulmonary disease, 
DPP4= dipeptidyl peptidase 4 inhibitor, 
FDA=Food and Drug Administration, 
HbA1c=hemoglobin A1C, 
MI=myocardial infarction, 
NH = Native Hawaiian, 
PI = Pacific Islander, 
SD=standard deviation, 
SGLT2i=sodium/glucose cotransporter-2 inhibitor,
T2D=type 2 diabetes mellitus.} 
\label{tab:table_1_period1}
\end{longtable}
